Clinical Research Directory
Browse clinical research sites, groups, and studies.
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
Sponsor: Bristol-Myers Squibb
Summary
The purpose of this study is to continue to provide elotuzumab and/or other study drugs to participants who have participated on a prior protocol investigating elotuzumab who are not able to receive commercial drug supply.
Official title: Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
67
Start Date
2016-07-15
Completion Date
2025-11-13
Last Updated
2025-06-05
Healthy Volunteers
No
Conditions
Interventions
Elotuzumab
Patients will continue to receive treatment with the investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
Dexamethasone
Patients will continue to receive treatment with non-investigational study drug by oral tablet administration at the last dose and schedule received in the previous study.
Dexamethasone
Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
Lenalidomide
Patients will continue to receive treatment with non-investigational study drug by oral capsule administration at the last dose and schedule received in the previous study.
Bortezomib
Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) or subcutaneous injection solution administration at the last dose and schedule received in the previous study.
Pomalidomide
Patients will continue to receive treatment with non-investigational study drug by oral capsule administration at the last dose and schedule received in the previous study.
Nivolumab
Patients will continue to receive treatment with the investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
Locations (41)
Local Institution - 0020
Tucson, Arizona, United States
Local Institution - 0017
Bakersfield, California, United States
Local Institution - 0022
Fountain Valley, California, United States
Local Institution - 0016
West Hollywood, California, United States
Local Institution - 0019
Denver, Colorado, United States
Local Institution - 0021
Jacksonville, Florida, United States
Local Institution - 0042
St. Petersburg, Florida, United States
Local Institution - 0009
Atlanta, Georgia, United States
Local Institution - 0003
Indianapolis, Indiana, United States
Local Institution - 0002
Boston, Massachusetts, United States
Local Institution - 0008
St Louis, Missouri, United States
Local Institution - 0004
New York, New York, United States
Local Institution - 0001
Bethlehem, Pennsylvania, United States
Local Institution - 0018
Dallas, Texas, United States
Local Institution - 0034
Heidelberg, Victoria, Australia
Local Institution - 0023
Antwerp, Belgium
Local Institution - 0011
Toronto, Ontario, Canada
Local Institution - 0010
Halifax, Canada
Local Institution - 0035
Athens, Greece
Local Institution - 0036
Budapest, Hungary
Local Institution - 0015
Ancona, Italy
Local Institution - 0012
Florence, Italy
Local Institution - 0013
Genova, Italy
Local Institution - 0043
Ravenna, Italy
Local Institution - 0044
Terni, Italy
Local Institution - 0014
Torino, Italy
Local Institution - 0046
Aomori, Aomori, Japan
Local Institution - 0047
Shibukawa-shi, Gunma, Japan
Local Institution - 0049
Osaka, Osaka, Japan
Local Institution - 0048
Koto-ku, Tokyo, Japan
Local Institution - 0050
Chiba, Japan
Local Institution - 0045
Kasama-shi, Japan
Local Institution - 0027
Chorzów, Poland
Local Institution - 0026
Warsaw, Poland
Local Institution - 0039
Warsaw, Poland
Local Institution - 0028
Bucharest, Romania
Local Institution - 0029
Iași, Romania
Local Institution - 0041
Barcelona, Spain
Local Institution - 0030
Toledo, Spain
Local Institution - 0031
Cebeci Ankara, Turkey (Türkiye)
Local Institution - 0032
London, United Kingdom